Inhibition of the MET Kinase Activity and Cell Growth in MET-Addicted Cancer Cells by Bi-Paratopic Linking.

[1]  A. Plückthun,et al.  High-Throughput Quantification of Surface Protein Internalization and Degradation. , 2019, ACS chemical biology.

[2]  J. Grandis,et al.  Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation , 2018, Oncogene.

[3]  D. Ribatti,et al.  Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study , 2018, Oncotarget.

[4]  W. Birchmeier,et al.  Characterization and structural determination of a new anti-MET function-blocking antibody with binding epitope distinct from the ligand binding domain , 2017, Scientific Reports.

[5]  P. Liu,et al.  Targeting MET in cancer therapy , 2017, Chronic diseases and translational medicine.

[6]  Hyori Kim,et al.  Progress of antibody-based inhibitors of the HGF–cMET axis in cancer therapy , 2017, Experimental & Molecular Medicine.

[7]  H. Koeppen,et al.  A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. , 2017, The oncologist.

[8]  L. Recht,et al.  Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Florent Cipriani,et al.  P13, the EMBL macromolecular crystallography beamline at the low-emittance PETRA III ring for high- and low-energy phasing with variable beam focusing , 2017, Journal of synchrotron radiation.

[10]  M. Shah,et al.  A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction. , 2016, The oncologist.

[11]  J. M. Lee,et al.  Novel strategy for a bispecific antibody: induction of dual target internalization and degradation , 2016, Oncogene.

[12]  Ying Tang,et al.  Abstract 873: A novel MET-EGFR bispecific antibody LY3164530 shows advantage over combining MET and EGFR antibodies in tumor inhibition and overcome resistance , 2016 .

[13]  P. Parren,et al.  A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. , 2016, Cancer research.

[14]  A. Plückthun,et al.  Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS–p110 crosstalk , 2016, Nature Communications.

[15]  V. Valero,et al.  Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Andreas Plückthun,et al.  Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. , 2015, Annual review of pharmacology and toxicology.

[17]  Andreas Plückthun,et al.  Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs. , 2014, Current opinion in structural biology.

[18]  Natalie de Jonge,et al.  Four individually druggable MET hotspots mediate HGF-driven tumor progression. , 2014, The Journal of clinical investigation.

[19]  M. Hallett,et al.  Dynamic Reprogramming of Signaling Upon Met Inhibition Reveals a Mechanism of Drug Resistance in Gastric Cancer , 2014, Science Signaling.

[20]  Andreas Plückthun,et al.  From DARPins to LoopDARPins: novel LoopDARPin design allows the selection of low picomolar binders in a single round of ribosome display. , 2013, Journal of molecular biology.

[21]  R. Govindan,et al.  Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Plückthun,et al.  Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. , 2013, Structure.

[23]  G. V. Vande Woude,et al.  Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent , 2013, Proceedings of the National Academy of Sciences.

[24]  Philip R. Evans,et al.  How good are my data and what is the resolution? , 2013, Acta crystallographica. Section D, Biological crystallography.

[25]  P. Zwart,et al.  Towards automated crystallographic structure refinement with phenix.refine , 2012, Acta crystallographica. Section D, Biological crystallography.

[26]  Carmen Birchmeier,et al.  Targeting MET in cancer: rationale and progress , 2012, Nature Reviews Cancer.

[27]  Ming-Sound Tsao,et al.  An overview of the c-MET signaling pathway , 2011, Therapeutic advances in medical oncology.

[28]  A. Plückthun,et al.  Bispecific Designed Ankyrin Repeat Proteins (DARPins) Targeting Epidermal Growth Factor Receptor Inhibit A431 Cell Proliferation and Receptor Recycling* , 2011, The Journal of Biological Chemistry.

[29]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[30]  Jie Qi,et al.  Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. , 2011, Cancer research.

[31]  Andreas Plückthun,et al.  Structural determinants for improved stability of designed ankyrin repeat proteins with a redesigned C-capping module. , 2010, Journal of molecular biology.

[32]  A. Krüger,et al.  A Disintegrin and Metalloproteinase-10 (ADAM-10) Mediates DN30 Antibody-induced Shedding of the Met Surface Receptor* , 2010, The Journal of Biological Chemistry.

[33]  S. Ogawa,et al.  Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. , 2010, Biochemical and biophysical research communications.

[34]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[35]  Wolfgang Kabsch,et al.  Integration, scaling, space-group assignment and post-refinement , 2010, Acta crystallographica. Section D, Biological crystallography.

[36]  I. Kasman,et al.  MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. , 2007, Cancer research.

[37]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[38]  E. Gherardi,et al.  Structure of the Human Receptor Tyrosine Kinase Met in Complex with the Listeria Invasion Protein InlB , 2007, Cell.

[39]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[40]  A. Bardelli,et al.  Genetic targeting of the kinase activity of the Met receptor in cancer cells , 2007, Proceedings of the National Academy of Sciences.

[41]  Andreas Plückthun,et al.  A designed ankyrin repeat protein evolved to picomolar affinity to Her2. , 2007, Journal of molecular biology.

[42]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[43]  S. Werner,et al.  c-Met is essential for wound healing in the skin , 2007, The Journal of cell biology.

[44]  N. Kohl,et al.  Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. , 2007, Cancer research.

[45]  M. Westphal,et al.  A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo , 2006, Clinical Cancer Research.

[46]  Dmitri I Svergun,et al.  Structural basis of hepatocyte growth factor/scatter factor and MET signalling. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Gayatry Mohapatra,et al.  Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[48]  P. Katsamba,et al.  Analyzing a kinetic titration series using affinity biosensors. , 2006, Analytical biochemistry.

[49]  A. Vaheri,et al.  Induction of hepatocyte growth factor/scatter factor by fibroblast clustering directly promotes tumor cell invasiveness. , 2005, Cancer research.

[50]  Christian Wiesmann,et al.  Crystal structure of the HGF β‐chain in complex with the Sema domain of the Met receptor , 2004, The EMBO journal.

[51]  O. Riesterer,et al.  Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells , 2004, Oncogene.

[52]  A. Plückthun,et al.  High-affinity binders selected from designed ankyrin repeat protein libraries , 2004, Nature Biotechnology.

[53]  S. Thorgeirsson,et al.  Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[54]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[55]  M. Matsuzaki,et al.  Proteasome‐dependent decrease in Akt by growth factors in vascular smooth muscle cells , 2003, FEBS letters.

[56]  J. Christensen,et al.  A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. , 2003, Cancer research.

[57]  T. Blundell,et al.  Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Andreas Plückthun,et al.  Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. , 2003, Journal of molecular biology.

[59]  P. Comoglio,et al.  Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. , 2002, Cancer research.

[60]  L. Schmidt,et al.  A novel germ line juxtamembrane Met mutation in human gastric cancer , 2000, Oncogene.

[61]  P. Choyke,et al.  Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. , 1999, The American journal of pathology.

[62]  L. Schmidt,et al.  Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. , 1999, Cancer research.

[63]  Frank McCormick,et al.  Akt activation by growth factors is a multiple-step process: the role of the PH domain , 1998, Oncogene.

[64]  E. Hudson,et al.  Met and hepatocyte growth factor/scatter factor expression in human gliomas. , 1997, Cancer research.

[65]  A. Plückthun,et al.  In vitro selection and evolution of functional proteins by using ribosome display. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[66]  S. Scherer,et al.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.

[67]  P. Godowski,et al.  Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins. Effects of mutations in the potential proteolytic cleavage site on processing and ligand binding. , 1992, The Journal of biological chemistry.

[68]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.

[69]  C. Cooper,et al.  Molecular cloning of a new transforming gene from a chemically transformed human cell line , 1984, Nature.

[70]  M. Ghate,et al.  Recent advances in the discovery of small molecule c-Met Kinase inhibitors. , 2018, European journal of medicinal chemistry.

[71]  A. Plückthun,et al.  Ribosome display: a technology for selecting and evolving proteins from large libraries. , 2011, Methods in molecular biology.